TrialBlood2011

Multi-institutional phase 2 study of the farnesyltransferase inhibitor tipifarnib (R115777) in patients with relapsed and refractory lymphomas.

Thomas E Witzig et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.